- Home
- CLSK vs APGE Comparison
CLSK vs APGE Comparison
Compare CLSK & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLSK
- APGE
- Stock Information
- Founded
- CLSK 1987
- APGE 2022
- Country
- CLSK United States
- APGE United States
- Employees
- CLSK N/A
- APGE N/A
- Industry
- CLSK Finance: Consumer Services
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLSK Finance
- APGE Health Care
- Exchange
- CLSK Nasdaq
- APGE Nasdaq
- Market Cap
- CLSK 2.6B
- APGE 3.0B
- IPO Year
- CLSK N/A
- APGE 2023
- Fundamental
- Price
- CLSK $9.45
- APGE $47.15
- Analyst Decision
- CLSK Strong Buy
- APGE Strong Buy
- Analyst Count
- CLSK 8
- APGE 5
- Target Price
- CLSK $22.71
- APGE $83.50
- AVG Volume (30 Days)
- CLSK 35.2M
- APGE 511.4K
- Earning Date
- CLSK 02-06-2025
- APGE 11-12-2024
- Dividend Yield
- CLSK N/A
- APGE N/A
- EPS Growth
- CLSK N/A
- APGE N/A
- EPS
- CLSK N/A
- APGE N/A
- Revenue
- CLSK $378,968,000.00
- APGE N/A
- Revenue This Year
- CLSK $154.93
- APGE N/A
- Revenue Next Year
- CLSK $34.56
- APGE N/A
- P/E Ratio
- CLSK N/A
- APGE N/A
- Revenue Growth
- CLSK 125.03
- APGE N/A
- 52 Week Low
- CLSK $6.41
- APGE $27.05
- 52 Week High
- CLSK $24.72
- APGE $72.29
- Technical
- Relative Strength Index (RSI)
- CLSK 35.03
- APGE 49.42
- Support Level
- CLSK $9.02
- APGE $43.26
- Resistance Level
- CLSK $9.84
- APGE $47.93
- Average True Range (ATR)
- CLSK 0.98
- APGE 3.12
- MACD
- CLSK -0.29
- APGE 0.12
- Stochastic Oscillator
- CLSK 9.22
- APGE 62.28
About CLSK CleanSpark Inc.
Cleanspark Inc is a bitcoin mining company. Through CleanSpark, Inc., and the Company's wholly owned subsidiaries, the company mines bitcoin. The company entered the bitcoin mining industry through its acquisition of ATL. Bitcoin mining is the sole reportable segment of the company.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.